Needles used to detect breast cancer in shortage from recall
A shortage of breast biopsy needles is impacting cancer detection in the United States, with the Food and Drug Administration predicting the scarcity will last until March 2027. This shortage stems from a recall initiated by Hologic Inc. in January due to reports of needle components dislodging and remaining in patients. Hologic, acquired by Blackstone Inc. and TPG Inc., is working to resolve the issue and aims to have the needles back on the market by the end of 2026, while also addressing past safety concerns with other products like the BioZorb tissue marker. AI
